How could new treatment options improve outcomes in FLT3-mutated AML?
ฝัง
- เผยแพร่เมื่อ 5 ก.ค. 2022
- During the 2022 ASCO Annual Meeting, the AML Hub spoke with Naval Daver, MD Anderson Cancer Center, Houston, US. We asked, How could new treatment options improve outcomes in FLT3-mutated acute myeloid leukemia (AML)?
Daver begins by outlining the nature of FLT3 mutations in patients with AML, including their association with a higher-risk prognosis, before discussing first- and second-generation FLT3 inhibitors and the studies that explored these. Daver goes on to outline a study on a venetoclax + gilteritinib combination in relapsed/refractory FLT3-mutated AML and its promising efficacy. Finally, Daver discusses studies aiming to improve outcomes for different patient groups, utilizing varying dosages and therapeutic combinations.
Hi Naval,
I really need your help as my father got diagnosed with AML. Can we please connect anytime when it's feasible for you